NVS
NOVARTIS (NVS) Wins Positive CHMP Opinion for Cosentyx in Polymyalgia Rheumatica
The EMA committee recommends Cosentyx for adults with PMR who fail steroids, which would make it the first IL-17A inhibitor cleared for the disease in Europe.
NVS
Market-moving news on Novartis (NYSE: NVS): filings, earnings, deals and other events, from REDFILED.